Evogene Current Deferred Revenue Over Time
| EVGN Stock | USD 1.81 0.03 1.69% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Evogene Performance and Evogene Correlation. Evogene |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evogene. If investors know Evogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.46) | Revenue Per Share | Quarterly Revenue Growth 0.398 | Return On Assets | Return On Equity |
The market value of Evogene is measured differently than its book value, which is the value of Evogene that is recorded on the company's balance sheet. Investors also form their own opinion of Evogene's value that differs from its market value or its book value, called intrinsic value, which is Evogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evogene's market value can be influenced by many factors that don't directly affect Evogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Current Deferred Revenue Analysis
Compare Evogene and related stocks such as Arcus Biosciences, Fate Therapeutics, and Surface Oncology Current Deferred Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RCUS | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 6.2 M | 7 M | 74.6 M | 102 M | 97 M | 91 M | 104.7 M | 60.2 M |
| FATE | 146 K | 146 K | 63 K | 2.1 M | 2.3 M | 2.4 M | 2.1 M | 2.1 M | 7.6 M | 2.8 M | 21.1 M | 21.5 M | 42.2 M | 685 K | 787.8 K | 748.4 K |
| PLUR | (256 K) | 792 K | 772 K | 626 K | 472 K | 640 K | 640 K | 640 K | 126 K | 126 K | 40 K | 112 K | 144 K | 124 K | 111.6 K | 106 K |
| LEXX | 13 K | 12.5 K | 12.5 K | 12.5 K | 12.5 K | 12.5 K | 17.1 K | 44.3 K | 44.3 K | 44.3 K | (225 K) | (225 K) | (225 K) | 5 K | 4.5 K | 4.7 K |
| ZVSA | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 765.7 K | 765.7 K | 765.7 K | 689.1 K | 777 K |
| BDRX | 68 K | 68 K | 68 K | 68 K | 68 K | 68 K | 68 K | 68 K | 68 K | 68 K | 68 K | 197 K | 197 K | 926 K | 1.1 M | 1.1 M |
| CANF | 219.5 K | 219.5 K | 219.5 K | 219.5 K | 219.5 K | 219.5 K | 321.6 K | 373.7 K | 926 K | 469 K | 334 K | 818 K | 783 K | 622 K | 715.3 K | 594.8 K |
| ICCC | 114 K | 8.2 K | 6.7 K | 6.7 K | 6.7 K | 33.9 K | 33.9 K | 24.1 K | 290.6 K | 290.6 K | 290.6 K | 290.6 K | 290.6 K | 290.6 K | 261.5 K | 248.4 K |
| CGEN | 1.2 M | 5.3 M | 5.3 M | 5.3 M | 1.8 M | 312 K | 312 K | 312 K | 774 K | 774 K | 668 K | 3.6 M | 325 K | 11.1 M | 12.8 M | 13.5 M |
| CLGN | 965.4 K | 965.4 K | 965.4 K | 965.4 K | 965.4 K | 965.4 K | 965.4 K | 965.4 K | 965.4 K | 942 K | 207 K | 32 K | 32 K | 32 K | 28.8 K | 27.4 K |
| PLX | 4.6 M | 6.1 M | 9.4 M | 9.4 M | 6.8 M | 504 K | 837 K | 26.9 M | 9.9 M | 16.3 M | 5.4 M | 8.6 M | 13.2 M | 2.9 M | 3.3 M | 3.1 M |
| CRVS | (2.6 M) | (2.6 M) | (2.6 M) | (2.6 M) | (2.6 M) | 223 K | 7 M | 7 M | 7 M | 7 M | 7 M | 7 M | 7 M | 7 M | 8 M | 8.4 M |
| ALDX | 8.8 K | 8.8 K | 8.8 K | 16.1 K | 400.2 K | 400.2 K | 400.2 K | 400.2 K | 400.2 K | 400.2 K | 400.2 K | 400.2 K | 400.2 K | 400.2 K | 460.3 K | 483.3 K |
Evogene and related stocks such as Arcus Biosciences, Fate Therapeutics, and Surface Oncology Current Deferred Revenue description
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.My Equities
My Current Equities and Potential Positions
Check out Evogene Performance and Evogene Correlation. To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Evogene technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.